Search alternatives:
changes decrease » largest decrease (Expand Search), change increases (Expand Search)
larger decrease » marked decrease (Expand Search)
significant a » significant _ (Expand Search), significant i (Expand Search), significant gap (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
changes decrease » largest decrease (Expand Search), change increases (Expand Search)
larger decrease » marked decrease (Expand Search)
significant a » significant _ (Expand Search), significant i (Expand Search), significant gap (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
7821
-
7822
Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
7823
Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
7824
Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
7825
Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
7826
Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
7827
MRI grading systems’ diagnostic accuracy for MD.
Published 2024“…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
-
7828
MRI-based cochlear hydrops grading and PLE in MD.
Published 2024“…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
-
7829
Cochlear hydrops classification in MRI systems.
Published 2024“…Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). …”
-
7830
Summary of subgroup analysis results.
Published 2025“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
-
7831
Original study data.
Published 2025“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
-
7832
S2 File -
Published 2025“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”
-
7833
Sequences of primers used for qRT-PCR.
Published 2025“…Notably, aerobic exercise significantly increased <i>FNDC5</i>/irisin expression (<i>P</i> < 0.05), and decreased NLRP3 and IL-18 levels (<i>P</i> < 0.01). …”
-
7834
A typical cross signalized intersection.
Published 2025“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”
-
7835
-
7836
-
7837
-
7838
-
7839
-
7840